Patents by Inventor Tomi-Pekka Tuomainen
Tomi-Pekka Tuomainen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070299025Abstract: The invention provides a method of identifying subject's susceptibility or predisposition to or risk of developing cardiovascular diseases such as myocardial infarction (MI) or coronary heart disease (CHD) by detecting gene polymorphisms and other gene mutations in a defensin gene from a biological sample of the subject and obtaining information concerning the family and medical history, blood, serum, plasma and urinary analytes of the subject. The invention also provides a multivariate model, a combination or algorithm of variables which best describes the probability of CHD, especially MI. The invention also relates to a test kit and software for accomplishing the method. The present invention also relates to a variant defensin gene.Type: ApplicationFiled: January 17, 2005Publication date: December 27, 2007Applicant: Oy Jurilab LtdInventors: Jukka Salonen, Mia Pirskanen, Jani Haarus, Tomi-Pekka Tuomainen, Faisel Yunus
-
Publication number: 20070148656Abstract: The present invention relates to variants in the catalase gene. The invention provides a method of identifying subject's susceptibility or predisposition to or risk of developing cancer, cancer death, CHD, and/or cerebrovascular stroke by detecting gene polymorphisms and other gene mutations in a biological sample from the subject. The invention also relates to a test kit and software for accomplishing the method. In addition, the invention provides a method for treating or preventing a human or animal suffering from cancer, CHD or cerebrovascular stroke, said method comprising a therapy enhancing catalase availability, production or concentration of the human subject or animal.Type: ApplicationFiled: February 11, 2005Publication date: June 28, 2007Inventors: Jukka Salonen, Jari Kalkkonen, Marja Marchesani, Mia Pirskanen, Tomi-Pekka Tuomainen, Pekka Uimari, Teemu Vilppo
-
Patent number: 7211387Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: GrantFiled: October 24, 2003Date of Patent: May 1, 2007Assignee: OY Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Publication number: 20060166205Abstract: The present invention provides a method of identifying subject's susceptibility to cardiovascular diseases or risk of developing myocardial infarction (MI) or cerebrovascular stroke by detecting gene polymorphisms and other gene mutations from a biological sample of the subject and optionally obtaining information concerning the family and medical history, blood, serum, plasma and urinary analytes of the subject. The invention also provides a multivariate model, a combination or algorithm of variables which best describes the probability of cardiovascular diseases, especially MI and stroke. The invention also relates to a test kit and software for accomplishing the method.Type: ApplicationFiled: October 7, 2003Publication date: July 27, 2006Applicant: OY JURILAB LTDInventors: Jukka Salonen, Tomi-Pekka Tuomainen, Mia Pirskanen
-
Publication number: 20060154249Abstract: The invention provides a method and kit for detecting or diagnosing a risk of or predisposition to diabetes or a metabolic syndrome in a subject, the method comprising the steps of providing a biological sample of the subject to be tested and detecting the presence or absence of a variant genotype of the human ?2B. adrenoceptor in the biological sample. The presence of the variant genotype indicates an increased risk of diabetes or a metabolic syndrome in said subject. The invention also relates to a method for the treatment of type 2 diabetes.Type: ApplicationFiled: December 11, 2003Publication date: July 13, 2006Applicant: Oy Jurilab LtdInventors: Jukka Salonen, Mia Pirskanen, Tomi-Pekka Tuomainen, Faisel Yunus
-
Publication number: 20040214264Abstract: This invention relates to a nucleic acid encoding a variant human DDAH protein and to said variant DDAH protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant DDAH protein. Further this invention relates to a method for detecting or diagnosing a risk of, or predisposition to, cardiovascular disease and diabetes in a subject, for selecting treatment in a subject and for selecting subjects for studies testing cardiovascular and diabetes drugs, a method for the treatment of type 2 diabetes as well as to transgenic animals.Type: ApplicationFiled: April 19, 2002Publication date: October 28, 2004Inventors: Veli-Pekka Valkonen, Jukka T. Salonen, Mia Pirskanen, Tomi-Pekka Tuomainen, Juha Laakso, Reijo Laaksonen
-
Publication number: 20040152637Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. This invention also relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal. This invention further relates to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.Type: ApplicationFiled: March 26, 2004Publication date: August 5, 2004Applicant: Oy Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
-
Publication number: 20040142349Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes , dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: ApplicationFiled: October 24, 2003Publication date: July 22, 2004Applicant: Oy Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Patent number: 6740746Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: GrantFiled: March 20, 2001Date of Patent: May 25, 2004Assignee: Oy Jurilab Ltd.Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Patent number: 6696556Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.Type: GrantFiled: April 5, 2001Date of Patent: February 24, 2004Assignee: OY Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssönen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
-
Publication number: 20030003453Abstract: This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes , dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.Type: ApplicationFiled: March 20, 2001Publication date: January 2, 2003Inventors: Jukka T. Salonen, Marja Marchesani, Tomi-Pekka Tuomainen, Jari Kaikkonen
-
Publication number: 20010016338Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to said variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant &agr;2B-adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor or said variant &agr;2B-adrenoceptor.Type: ApplicationFiled: April 5, 2001Publication date: August 23, 2001Applicant: OY Juvantia Pharma Ltd.Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen